QIAGEN N.V. (QGEN)

↓ Download CSV

CIK 0001015820 · NYSE · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated P7
  • Fiscal year ends Dec 31

In fiscal 2025, QIAGEN N.V. reported revenue of $2.09B, up 5.7% from the prior year. The company was profitable, with a net margin of 20.3% and a gross margin of 62.2%.

Key ratios (FY2025)

62.2%
Gross margin
22.3%
Operating margin
20.3%
Net margin
11.2%
Return on equity
+5.7%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$2.09B$1.98B$1.97B$2.14B$2.25B$1.87B$1.53B$1.50B$1.42B$1.34B
Cost of Revenue$790.50M$1.01B$731.62M$756.96M$800.84M$637.63M$521.16M$500.89M$494.98M$493.34M
Gross Profit$1.30B$967.35M$1.23B$1.38B$1.45B$1.23B$1.01B$1.00B$922.56M$844.65M
Operating Income$465.85M$97.71M$409.94M$531.46M$630.08M$386.43M-$26.14M$266.58M$153.42M$98.83M
Net Income$424.88M$83.59M$341.30M$423.21M$512.60M$359.19M-$41.45M$190.38M$40.39M$80.40M
EPS (Diluted)$1.94$0.37$1.48$1.84$2.21$1.53$-0.18$0.82$0.17$0.34
Total Assets$6.28B$5.69B$6.12B$6.29B$6.15B$5.87B$5.24B$5.75B$5.04B$4.31B
Shareholders' Equity$3.78B$3.57B$3.81B$3.47B$3.10B$2.80B$2.54B$2.63B$2.54B$2.61B
Cash & Equivalents$839.00M$663.55M$668.08M$730.67M$880.52M$597.98M$623.65M$1.16B$657.71M$439.18M
Operating Cash Flow$654.33M$673.55M$459.45M$715.26M$639.00M$457.81M$330.84M$359.50M$286.78M$341.60M
Capital Expenditures$201.05M$167.17M$149.71M$129.22M$189.90M$132.79M$117.95M$109.77M$90.08M$74.54M
Shares Outstanding218.88M224.72M230.62M230.14M232.03M234.21M226.78M233.46M233.01M238.99M
Dividends Per Share$0.25